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Abstract 
Purpose: To assess the influence of smoking cigarettes on the pharmacokinetics of the antiplatelet 
drug, clopidogrel. 
Methods: Thirty four male patients, mean age and weight of 59.3 years and 81.1 kg, respectively, who 
underwent percutaneous coronary intervention (PCI), took part in the study. Each subject received an 
oral loading dose of 600 mg clopidogrel eight tablets, each 75 mg). Clopidogrel carboxylate plasma 
level was measured and non-compartmental analysis was used to determine peak plasma 
concentration (Cmax), time to achieve peak plasma concentration (Tmax), elimination half-life (t1/2e), and 
area under the curve (AUC0-∞). Other parameters measured include gamma-glutamyltransferase 
enzyme (GGT), low density lipoprotein cholesterol (LDL-cholesterol), blood urea nitrogen (BUN) and 
platelet count. 
Results: Nineteen patients were smokers (55.9 %). Smokers had higher levels of GGT compared to 
non-smokers (31.73 ± 14.42 vs. 21.63 ± 11.41 IU/L, p = 0.08) as well as higher levels of LDL-cholesterol 
(116.79 ± 42.08 vs. 87.07 ± 27.34 mg/dl, p = 0.041, respectively). Smokers had shorter half-life 
(smokers: 3.47 ± 1.9 h vs. non-smokers: 5.83 ± 4.09 h, p = 0.012). Smoking behavior had no influence 
on Cmax (p = 0.16), AUC0-∞ (p = 0.65) or Tmax (p = 0.91). In general, the pharmacokinetic parameters 
were characterized by considerable inter-individual variation (Cmax = 23.2 ± 8.79 µg/ml, coefficient of 
variation (CV) = 37.9 %), (Tmax = 1.71 ± 1.15 h, CV = 67.2 %), (AUC0-∞ = 120.97 ± 44.4 µg.h/ml, CV = 
36.7 %) and (t1/2e = 4.57 ± 3.15 h, CV = 68.9 %). 
Conclusion: Smoking behavior may not be a significant determinant of the pharmacokinetics of 
clopidogrel following oral administration of 600 mg dose in patients undergoing PCI.  
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Clopidogrel is an antiplatelet agent which 
selectively inhibits the binding of adenosine 
diphosphate (ADP) to its platelet receptor 
(P2Y12) and blocks the subsequent platelet 
aggregation [1]. Clopidogrel is particularly 
important in prevention of coronary thrombosis 
and highly valuable in patients undergoing 
coronary revascularization [2,3]. Recently 
published studies revealed a marked inter-
individual variability to clopidogrel inhibition of 
ADP-induced platelet aggregation [4]. It is 
estimated that laboratory clopidogrel non-
responsiveness can be found in 20 % of patients 
undergoing percutaneous coronary intervention 
(PCI). This is alarming as the consequences of 
stent thrombosis are grave with high rates of 
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death, myocardial infarction (MI), and repeat 
vascularization [5].  
 
The causal link between smoking and premature 
coronary arterial disease (CAD) is well 
demonstrated [6]. Smoking cessation is the 
single most important intervention for primary 
and secondary prevention of CAD [7]. 
Furthermore, a recent large meta-analysis of 
prospective double blind randomized controlled 
trials of paclitaxel-eluting stents found that early 
stent thrombosis (< 30 days) was strongly and 
independently associated with smoking with an 
overall mortality rate of 41.2 % [5].  
 
A phenomenon termed “Smoking Paradox” had 
been noticed with smokers on clopidogrel 
therapy, in which smoking enhances clopidogrel 
pharmacodynamics, and smoker patients on 
clopidogrel had lower platelets reactivity [8]. 
Additionally it showed a lower incidence of all-
cause mortality and that treatment is more 
effective at reducing the rate of cardiovascular 
death, myocardial infarction, or urgent 
revascularization through 30 days among those 
who smoked ≥ 10 cigarettes/day compared with 
those who did not [8-10]. Other evidence shows 
that current smokers (≥ 10 cigarettes/day) had 
low platelet reactivity [11] and lower active GP 
IIb/IIIa expression [12] compared with non-
smokers. This finding contradicts the very well 
established notion that smoking is an 
independent risk factor for coronary vascular 
disease (CVD) [13].  
 
Our objective is to assess the effect of tobacco 
smoking, on the pharmacokinetics of clopidogrel 
among patients receiving 600 mg clopidogrel and 




Study population  
 
Patients (men) who were admitted to Jordan 
University Hospital for catheterization and 
underwent PCI would be eligible for the entry into 
this study if they were given 600 mg of Plavix® 
(clopidogrel), and consented to participate. 
Patients were excluded if they were known to 
have hepatitis B infection or carrier of respective 
antigen; donated blood within last 2 months; 
have allergic diathesis or any significant allergic 
disease; have GI diseases or hepatic disease; 
were pregnant; have creatinine clearance < 
60ml/min; or diagnosed with heart failure with 
NYHA class 4.  
 
The study was approved by local Research 
Ethics Committees of the Jordan University 
Hospital (approval reference number 
M/C/A/111/1519) and informed consent was 
obtained from all participants after having been 
informed verbally by the medical supervisor 
about the need to withdraw extra blood samples 
for pharmacokinetic analysis. The decision to 
give or not to give 600 mg clopidogrel was solely 
the responsibility of the treating cardio-surgeon 
performing the PCI. Various laboratory tests 
were conducted prior to the procedure for each 
patient. These include serum creatinine, blood 
urea nitrogen and sodium; liver function (total 
proteins, albumin, aminotransferases, and 
alkaline phosphatase); lipid profile and complete 
blood count. 
 
To be included in the study, smokers were 
defined as those who smoked least 3 cigarettes 
per day for at least one year. Non-smokers were 
defined as patients who never smoked cigarettes 
or water pipe. Patients who used to smoke and 
quitted (i.e., ex-smokers) were not included in the 
study irrespective of the period of smoking 
cessation. 
 
Sample size calculation 
 
The sample size needed to evaluate the 
influence of smoking on Cmax of clopidogrel 
carboxylic acid metabolite was calculated using 
equation 1: 
 
N = 2x(SD/Δ)2x(Z1-α/2+Z1-β)+0.25(Z1-α/2) ……… (1) 
 
where SD is the estimated standard deviation; Δ 
is the practical significant difference of the mean 
(33 % of mean); Z1-α/2 is the level of significance 
(α level = 0.05); and Z1-β is the power of the study 
(β level = 0.2). We assumed AUC0-∞ (198.6 ± 
52.4 µg.h/ml) based on previously published data 
[14]. The minimum sample size to detect a 
difference of at least 60 µg.hr /ml in AUC0-∞ was 
calculated to be 12. The sample size was further 
increased to 15 to account for potential data 
points below lower limit of detection (0.5 µg/ml) 
over the observation period (8 h).  
 
Intervention and sample collection, chroma-
tographic conditions and pharmacokinetic 
calculations 
 
The blood sampling, condition of HPLC and 
pharmacokinetics parameters were reported in 
previous work [15]. In summary, a whole blood 
samples from patients were drawn into 
heparinized test tubes at different time points. 
Plasma samples were separated and 
immediately stored at -80 °C until analysis. The 
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plasma level of clopidogrel carboxylic acid were 
determined by reverse-phase high-performance 
liquid chromatographic method, where the 
separation achieved using isocratic mobile 
phase. A Dionex® HPLC autosampler system 
was used All separations were performed at 
room temperature. Detection was monitored at 
220 nm. 
 
The pharmacokinetic parameters of clopidogrel 
carboxylic acid metabolite were estimated by 
standard non-compartmental methods using 
KineticaTM 2000 Version 4.2 (Innaphase, 
Philadelphia, PA, USA). 
 
Laboratory parameter measurements 
 
LDL, BUN, GGT and other parameters were 
measured by standardized and validated 




Statistical analysis was performed using SPSS© 
software (version 16.0; SPSS, Inc, Chicago, IL). 
Data were expressed as mean ± SD. Coefficient 
of variation (CV) was calculated by as 
(mean/SD)*100. Normal probability distribution of 
pharmacokinetic parameters was determined 
visually by the probability plot (P-P) and quantile-
quantile (Q-Q) plot and examining the 
Kolmogorov-Smirnov-Lilliefors test (K-S test). 
Equality of variance was assessed by levene's 
test. The effect of smoking on pharmacokinetic 
parameters (Cmax, Tmax and AUC0-∞) was 
assessed by independent Student t-test. 
However, Mann-Whitney was utilized to test the 
effect of smoking on t1/2e.  Linear association 
between pharmacokinetic parameter, t1/2e, and 
laboratory data (LDL, platelet, BUN and GGT) 






Thirty four male patients received 600 mg 
clopidogrel loading dose in the study. Patients 
had an average age of 59.3 ± 9.0 years (range: 
44 - 82 years), mean height of 173.7 ± 7.0 cm 
(range: 155 - 187 cm), average weight of 81.4 ± 
12.6 kg (range: 65 – 116 kg), and mean BMI of 
26.96 ± 4.25 kgm-2 (range: 21.7 – 38.0 kgm-2) 
(Table 1). 
 
With regard to laboratory results, patients had 
normal kidney function (serum creatinine, blood 
urea nitrogen and sodium); liver function (total 
proteins, albumin, aminotransferases, and 
alkaline phosphatase); lipid profile and complete 
blood count (Table 2). 
 
More than one half of participants were smokers 
(n = 19). All smokers except two smokers 
smoked more than 10 cigarettes per day with a 
mean of 35.6 (range: 3 - 80) cigarettes per day. 
Smokers and non-smokers had similar medical 
conditions, prior to admission medications, 
demographic characteristics, laboratory and 
physical examination except for one parameter 
LDL-Cholesterol. Smokers had higher levels of 
LDL-cholesterol (116.79 ± 42.08 vs. 87.07 ± 
27.34 mg/dl, p = 0.041). 
 
 
Table 1: Demographic and clinical characteristics of recruited patients 
  
Parameter Smokers (N = 19) Non-smokers (N = 15) 
Age (years, ± SD) 56.7±10.2 62.6±5.8 
Body mass index (kg/m2, ±SD) 29.3±3.5 27.9±5.08 















Pre-admission medication history 
Aspirin 
Beta adrenergic receptors blockers  
ACEIs / ARBs 
HMGCo-reductase inhibitors 













ACEI, angiotrensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; HMGCoA-reductase inhibitor, 
Hydroxy-methyl-glutaryl-CoA reductase inhibitor 
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Table 2: Biochemical, heamatological and renal profile 
of patients included in the study 
 
Parameter Mean ± SD 
Kidney function 
Na conc. (mEq/L) 139±2.9 
K conc. (mEq/L) 4.64±0.53 
Scr (mg/dl) 0.80±0.19 
BUN (mg/dl) 16.1±4.5 
Liver function 
Total protein (g/L) 6.54±0.44 
Albumin (g/L) 3.85±0.34 
ALT (IU/L) 26.92±16.07 
AST (IU/L) 26.71±12.04 
GGT (IU/L) 27.46±13.9 
LDH(IU/L) 371.18±106.56 
 Complete blood count 
RBC (106/mm3) 4.64±0.53 
WBC (103/mm3) 8.8±2.36 
Platelets (103/mm3) 222.07±62.7 
Hgb (g/dl) 13.1±1.7 
Other tests 
Total Cholesterol (mg/dl) 160.7±42.92 
LDL-cholesterol (mg/dl) 102.48±38.2 
HDL-cholesterol (mg/dl) 32.05±6.92 
Triglycerides (mg/dl) 167.85±91.25 
Scr, Serum creatinine; BUN, blood urea nitrogen; ALT, 
alanine aminotransferase; AST, aspartate 
aminotransferase; GGT, Gamma-glutamyltransferase ; 
LDH, lactate dehydrogenase; RBC, red blood cell; 
WBC, white blood cell; Hgb, hemoglobin 
 
Another two laboratory parameters were also 
different between two groups of study, where 
smokers had higher GGT levels (31.73 ± 14.42 
vs.21.63 ± 11.41, p = 0.08) but lower level of 
blood urea nitrogen (12.94 ± 2.6 vs. 15 ± 3.06 
mg/dl, p = 0.073) (Table 3). 
 
None of these differences is expected to be 
clinically relevant as they were all within normal 
range. Additionally, none of these differences is 





The primary pharmacokinetic parameters of 
clopidogrel carboxylic acid metabolites are 
reported in table 4. Independent of smoking 
status, the plasma levels were characterized with 
significant variability (Cmax = 23.21 ± 8.79 µg/ml, 
CV = 37.9 %), (Tmax = 1.71 ± 1.15 h, CV = 67.2 
%), (AUC0-∞ = 120.97 ± 44. 4 µg.h/ml, CV = 36.7 
%), and (t1/2e = 4.57 ± 3.15 h, CV = 68.9 %).  
 
Regarding the two groups of study, smokers had 
shorter half-life (p = 0.012). However, smoking 
behavior had no statistically significantly 
influence on Cmax, AUC0-∞ nor on Tmax (Table 4). 
 
Since differences between smokers and non-
smokers were found for variables such LDL, 
GGT and BUN, it was necessary to analyze the 
possible contribution of these co-variables to the 
explanation of the significant differences found 
for t1/2e. 
 
Accordingly, a correlation study was done for t1/2e 
against these variables (Table 5). 
 
There was no statistically significant correlation 
between t1/2e and LDL-Cholesterol, GGT or BUN 
(Table 5). The only significant correlation was 
with smoking status that decreases t1/2e by 2.36 




Clopidogrel is an important antiplatelet agent that 
has application in the primary and secondary 
prevention of cardiovascular complications 
especially among patients unable to take aspirin. 
In patients who undergo PCI, dual antiplatelets 
consisting of aspirin and clopidogrel is the 
regimen of choice to prevent thrombotic 
complications [2,16]. Following oral 
administration, clopidogrel is rapidly absorbed 
and undergoes extensive hepatic metabolism 
[17]. The parent drug is inactive and hepatic 
biotransformation is necessary for its antiplatelet 
activity [18]. The inactive carboxylic acid 
metabolite is the most abundant species found in 
plasma at high concentrations [17]. 
 










LDL 87.07±27.34 116.79±42.08 0.041‡ 
GGT 21.63±11.41 31.73±14.42 0.08§ 
BUN 15.0±3.06 12.94±2.60 0.073‡ 
Data were missing for four patients; ‡Differences were assessed using independent t-test; §Differences were 
assessed using Mann-Whitney test; LDL-Cholesterol, low density lipoprotein; GGT, Gamma-glutamyl transferase; 
BUN, blood urea nitrogen 
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            Table 5: Pearson correlation coefficient between elimination half-life and patients’ biochemical data 
 
Parameter Pearson  correlation         p value 
BUN 0.293 0.123 
LDL-cholesterol  -0.17 0.424 
GGT -0.083 0.703 
      BUN, blood urea nitrogen; LDL-Cholesterol, low density lipoprotein; GGT, Gamma-glutamyl transferase 
 
Pharmacokinetic studies of clopidogrel have 
been performed by measuring plasma levels of 
either the parent drug [19] or the carboxylic acid 
metabolite as an indirect approach [17,20]. It has 
been proposed that information on the absorption 
and elimination of clopidogrel after oral 
administration can be derived from the 
pharmacokinetics of carboxylate metabolite [17].  
 
This research does not address the interaction of 
smoking behavior with pharmacodynamics of 
clopidogrel as there are numerous papers 
published with this regards [11,12,21]. On the 
other hand only one publication was found on the 
interaction at the pharmacokinetics level of 75mg 
clopidogrel in patients [8].  
 
The current study aimed to evaluate the effect of 
smoking on pharmacokinetic parameters of 
clopidogrel loading dose of 600 mg in CAD 
patients planned for PCI. Influence of smoking is 
important to study as smoking has been 
associated with platelet hyperactivity, increased 
cardiovascular risk [6] and it has been found 
recently to alter the pharmacokinetics 
parameters of 75 mg clopidogrel in healthy 
volunteers [22], as well as in patients [8]. 
 
The current study revealed that smoking affected 
at least one pharmacokinetics parameters of 
clopidogrel carboxylate in smokers. Smokers had 
lower AUC0-∞ by 11.5 % (p = 0.65) and had 
shorter half life by 40.5 % (p = 0.012). It has 
been proposed that smoking may change drugs’ 
pharmacokinetics through higher gastric 
secretion [23] and decreased gastric blood flow 
[24]. It is unlikely that the effects of smoking on 
stomach acidity and gastric blood supply 
contributed to the observed difference on half life 
as Cmax and AUC0-∞ were not different between 
smokers and non-smokers. On the other hand, 
smoking has been found to interfere with a 
variety of CYP isoforms; to induce CYP1A2 
[25,26], to interact with CYP2C19 [27], and to 
increase the expression of CYP3A5 [28,29]. 
Alternatively, smoking was proposed to increase 
renal clearance [30]  by induction of a renal 
transport protein[30], thus may decrease the 
elimination half-life as it has been noticed in the 
current study and in a previous work [22]. 
 
The finding of current study parallel our previous 
work that linked smoking behavior with 
clopidogrel pharmacokinetics in healthy male 
volunteer [22], where smokers had shorter half-
life of carboxylic acid metabolite after 
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administration of a 75 mg single dose clopidogrel 
by 35 %.  Smokers also had lower Cmax and 
AUC compared to non-smokers [22], this also 
was noticed by the PARADOX study, in which 
smokers on Clopidogrel therapy had lower Cmax 
and AUC compared to non-smokers, and had 
higher exposure to clopidogrel active metabolite 
compared to non-smokers that can be explained 
by higher activation of CYP1A2 enzyme as 
mentioned earlier [8].  
 
It was established that smoking is one of the 
major risk factors for cardiovascular diseases, 
dyslipidemia, diabetes, cancers, respiratory 
diseases and other diseases [31]. Paradoxically 
it has been found recently that smoking 
potentiates the effect of clopidogrel [8,10,11], 
where current smokers on clopidogrel therapy 
showed lower platelet activity and greater platelet 
inhibition compared to non-smokers. Also, it has 
been found that smokers show lower active 
glycoprotein IIb/IIIa expression compared to non-
smokers [12] that potentiates antiplatelet effect. 
This may be because of the way that platelet 
reactivity is being evaluated, where the same 
number of platelet is used to assess platelet 
inhibition post any type of intervention to be 
studied.  
 
The finding of no effect of smoking on 
pharmacokinetics of clopidogrel is of importance 
as there is strong evidence that indicates a 
publication bias against negative findings.  
Assessment of the number of meeting-abstracts 
that turn onto full papers revealed that a trial 
showing a benefit of a drug or device has much 
greater chance of full publication than does a trial 
showing no benefit [32]. 
 
Of interest is the observed differences between 
smokers and non-smokers in relation to the level 
of LDL-cholesterol [33,34], GGT [35] and blood 
urea nitrogen [36].  
 
Reasons behind these differences are not yet 
well known. Liver enzyme GGT is higher in 
smokers because cigarette smoking might 
induce liver injury by enhancing lipid membrane 
peroxidation and cause cell destruction that is 
responsible for the liver enzyme leakage to 
systemic circulation.  
 
Lipid profile seems to be altered among smokers. 
Lower HDL level and higher LDL level have been 
noticed among different ethnic groups. The high 
LDL level among smokers has been linked to 
increase lipolysis by stimulation of the adrenal 
system, increasing catecholamine, and hence 
increasing the TG, free fatty acids and VLDL-
cholesterol. Nicotine is one of the main 
constituents of cigarette that has been found to 
cause increase in triglyceride, cholesterol and 
VLDL-cholesterol levels and to decrease HDL-
Cholesterol levels. Also it has been found that  
nicotine increases the circulatory pool of 
atherogenic LDL-cholesterol via accelerated 
transfer of lipids from HDL-cholesterol and 
impaired clearance of LDL-cholesterol from 
plasma compartment therefore it increases the 
deposition of LDL-cholesterol.  
 
Many factors could cause a lower level of serum 
urea compared to non-smokers, of these; 
smokers had been found to consume less 
quantity of dietary proteins compared to non-
smokers which may cause lower amount of urea 
level and lower level to be excreted [36].  
 
Limitations of the study 
 
The findings of this paper are limited by the small 
sample size included in the study. The needed 
sample size was calculated based on previously 
published pharmacokinetics parameters of 600 
mg clopidogrel [14]. The difference to be 
detected between smokers and non-smokers 
was set at 33 % as a clinically significant 
difference was hypothesized to equal or to be 
larger than intrinsic variability reported in the 
pharmacokinetics behavior of clopidogrel 
[14,17,20,22]. The AUC calculated for the 34 
patients was lower than anticipated in the sample 
size calculation, and our study would not have 
been able to detect the specified difference in 
AUC between smokers and non-smokers. 
 
The recruited patients suffered from multiple 
medical conditions and were on a large list of 
medications with the potential to confound the 
finding of current study. It is practically difficult to 
select patient who are not on medications that 
may interfere with pharmacokinetics of 
clopidogrel as all of them are elders with multiple 
diseases. Still, the study population is reflection 
of actual medical practice.  
 
The study was limited to male gender, further 
research has to include women as gender 
differences may have a more pronounced effect 
on cytochrome (CYP) 3A4 [26].  
 
Moreover, the sampling time in the current study 
was short as it was limited to 8 h post treatment. 
More time is needed (24-48 h) to have a better 
estimation of terminal half-life. Unfortunately, this 
is not feasible in real life situation where real 
patients are being recruited and most of them are 
discharged after less than 24 h post stenting. It 
should be noted that several other studies 
terminated sampling by 8 h or even less [14,37].  
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Additionally, the study assumed that changes in 
clopidogrel carboxylate mirror changes in the 
active thiol metabolite. Clearly, more research is 
needed to clarify the effect of smoking on the 





Findings from this study reveal that smoking 
affects at least one clopidogrel carboxylate 
pharmacokinetic parameter in smokers, but it 
may not be a significant determinant of the 
pharmacokinetics of 600 mg clopidogrel in 
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